medicine-products/examwriter-electronic-medical-records-9584-1/;msg90356

Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3 AEterna Zentaris Announces Appointment of New Board Member 2 Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2

[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain [0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease [0] AEterna Zentaris Announces Appointment of New Board Member [0] Waters Ships First Units of SYNAPT G2 Mass Spectrometer

Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10 New study suggests the brain predicts what eyes in motion will see 55304 1 New study suggests the brain predicts what eyes in motion will see 55304 2 SRNL automakers to develop high performance wireless sensors networks 9693 1 SRNL automakers to develop high performance wireless sensors networks 9693 2 SRNL automakers to develop high performance wireless sensors networks 9693 3 New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 1 New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 2 New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 3 New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 4 New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 5

[0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology [0] Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection [0] Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab